Gene · 4055
Papers3,299
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,299
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pathogenesis and therapeutic implications of EBV-associated epithelial cancers. | Front Oncol | 2023 | 37901329 | PubTator, text mining | PubMed |
| Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4. | Int J Mol Sci | 2023 | 37894816 | PubTator, text mining | PubMed |
| TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors. | Biomedicines | 2023 | 37893178 | PubTator, text mining | PubMed |
| The RELT Family of Proteins: An Increasing Awareness of Their Importance for Cancer, the Immune System, and Development. | Biomedicines | 2023 | 37893069 | PubTator, text mining | PubMed |
Fish Collagen Peptides Enhance Thymopoietic Gene Expression, Cell Proliferation, Thymocyte Adherence, and Cytoprotection in Thymic Epithelial Cells via Activation of the Nuclear Factor-κB Pathway, Leading to Thymus Regeneration after Cyclophosphamide-Induced Injury. | Mar Drugs | 2023 | 37888466 | PubTator, text mining | PubMed |
| Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. | Commun Med (Lond) | 2023 | 37880538 | PubTator, text mining | PubMed |
| Advancements in CRISPR screens for the development of cancer immunotherapy strategies. | Mol Ther Oncolytics | 2023 | 37876793 | PubTator, text mining | PubMed |
| A Specialized Epithelial Cell Type Regulating Mucosal Immunity and Driving Human Crohn's Disease. | bioRxiv | 2023 | 37873404 | PubTator, text mining | PubMed |
| Advances in proteomics: characterization of the innate immune system after birth and during inflammation. | Front Immunol | 2023 | 37868984 | PubTator, text mining | PubMed |
| Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma. | Front Immunol | 2023 | 37868967 | PubTator, text mining | PubMed |
| Cross-tissue patterns of DNA hypomethylation reveal genetically distinct histories of cell development. | BMC Genomics | 2023 | 37858046 | PubTator, text mining | PubMed |
| Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis. | Cells | 2023 | 37830598 | PubTator, text mining | PubMed |
| Analysis of Free Circulating Messenger Ribonucleic Acids in Serum Samples from Late-Onset Spinal Muscular Atrophy Patients Using nCounter NanoString Technology. | Cells | 2023 | 37830588 | PubTator, text mining | PubMed |
| Prognostic and immunological characterization of diffuse large B-cell lymphoma evaluated by co-stimulatory molecular-related features. | Heliyon | 2023 | 37809743 | PubTator, text mining | PubMed |
| Integrative analysis of cancer-associated fibroblast signature in gastric cancer. | Heliyon | 2023 | 37809716 | PubTator, text mining | PubMed |
| Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity. | Front Immunol | 2023 | 37809103 | PubTator, text mining | PubMed |
| Mosaic loss of the Y chromosome in human neurodegenerative and oncological diseases. | Vavilovskii Zhurnal Genet Selektsii | 2023 | 37808213 | PubTator, text mining | PubMed |
| Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. | Front Immunol | 2023 | 37795079 | PubTator, text mining | PubMed |
| Identification of prognostic and diagnostic signatures for cancer and acute myocardial infarction: multi-omics approaches for deciphering heterogeneity to enhance patient management. | Front Pharmacol | 2023 | 37781709 | PubTator, text mining | PubMed |
| A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: differentiating pentameric and modified CRP isoform effects. | Front Immunol | 2023 | 37781355 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4055/papers?page=9